SciSparc Granted FDA Approval for Phase IIb Trial of Novel Tourette Syndrome Therapy
Oct 1, 2024
Clinicaltrial Invest Information
Novartis's Kisqali Demonstrates a 28.5% Decrease in Recurrence Risk in Early Breast Cancer Patients
Sep 17, 2024
SciSparc Ltd. (NASDAQ:SPRC) Soars on Positive Clinical Trial Launch
Nov 25, 2023